What is Neuroplast?
Founded in 2014 by physician Johannes de Munter and neurologist Erik Wolters, Neuroplast operates at the intersection of stem cell technology and neurology. Headquartered at the Brightlands Chemelot Campus in the Netherlands, the company focuses on the development of autologous cell products designed to mitigate the impact of chronic, inflammation-driven neurological disorders. Unlike traditional pharmaceutical approaches, Neuroplast utilizes the patient's own biological material to foster recovery and improve quality of life, positioning itself as a leader in the burgeoning field of personalized regenerative medicine.
The company's market position is bolstered by its strategic location within a high-tech innovation hub, allowing for seamless collaboration with academic institutions and industry partners. By targeting high-unmet-need conditions, Neuroplast has carved out a niche that combines rigorous clinical science with a clear commercial pathway, attracting significant interest from regional development agencies and specialized venture capital firms.
How much funding has Neuroplast raised?
Neuroplast has raised a total of $11.5M across 1 funding round:
Series B
$11.5M
Series B (2021): $11.5M with participation from Brightlands Venture Partners and Liof
Key Investors in Neuroplast
Brightlands Venture Partners
Brightlands Venture Partners invests in innovative companies addressing global challenges in health, agrifood, and renewable chemistry, providing active support to founders building scalable businesses.
Liof
LIOF is the regional development agency for Limburg, dedicated to supporting innovative entrepreneurs through financing, networking, and strategic advice to enhance regional competitiveness.
What's next for Neuroplast?
Looking ahead, the strategic deployment of the $11.5M will likely focus on the expansion of clinical trial capacity and the optimization of manufacturing processes for its lead therapeutic candidates. As the company transitions from early-stage development to more advanced clinical phases, the focus will shift toward securing regulatory approvals and establishing long-term efficacy data. The continued support from its investor base suggests a long-term commitment to scaling the company's infrastructure, potentially setting the stage for future international expansion or strategic partnerships with global pharmaceutical entities. The company remains committed to its core objective of providing transformative treatment options for patients suffering from debilitating neurological conditions, ensuring that its growth trajectory remains aligned with both scientific advancement and commercial viability.
See full Neuroplast company page
